Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAIR-HF-style phase III trial of intravenous ferric carboxymaltose in chronic heart failure with iron deficiency
NL-OMON32525Phase 3Not yet recruiting
- Sponsor
- Vifor Pharma
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ferric carboxymaltose in heart failure (HF) and iron deficiency anemia (IDA), sponsored by Vifor Pharma. Planned start Nov 2008; status: not yet recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure (HF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NL-OMON32525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32525.